18-Apr-2024
Investor Presentation - April 2024
11-Apr-2024
3QFY2024 Results and Investor Conference Call
10-Apr-2024
Quarterly Activities Report and Appendix 4C
2-Apr-2024
2024 EGM Letter to Shareholders and Proxy
2-Apr-2024
2024 EGM Notice of Meeting and Proxy
28-Mar-2024
Nyrada Commences Key Brain Injury Program Preclinical Study
15-Mar-2024
Notice of Change of Interests of Substantial Securityholder
15-Mar-2024
Notice of Change of Interests of Substantial Securityholder
15-Mar-2024
Cleansing Statement
15-Mar-2024
Application for quotation of securities - NYR
15-Mar-2024
Amended and Restated Certificate of Incorporation and Bylaw
14-Mar-2024
Change of Director's Interest Notice - CC
14-Mar-2024
Change of Director's Interest Notice - RW
14-Mar-2024
Change of Director's Interest Notice - MF
14-Mar-2024
Change of Director's Interest Notice - JM
14-Mar-2024
Notification of cessation of securities - NYR
6-Mar-2024
Nyrada Successfully Raises $1.755 Million via Placement
6-Mar-2024
Proposed issue of securities - NYR
6-Mar-2024
Proposed issue of securities - NYR
4-Mar-2024
Trading Halt
28-Feb-2024
Nyrada CEO James Bonner interview with 180 Markets
28-Feb-2024
Significant Neuroprotection in NYR Preclinical Brain Injury
20-Feb-2024
Nyrada Half Year Results FY2024
20-Feb-2024
Appendix 4D and Half Year Report to 31 December 2023
19-Jan-2024
Amended and Restated Certificate of Incorporation and Bylaws
17-Jan-2024
Quarterly Activities Report and Appendix 4C
8-Dec-2023
Nyrada Receives A$3.54M R&D Tax Incentive Rebate
20-Nov-2023
Nyrada Annual General Meeting Results
20-Nov-2023
Nyrada AGM 2023 CEO Presentation
20-Nov-2023
Nyrada AGM 2023 Chair Address
1-Nov-2023
2023 AGM Chair Letter to Shareholders
17-Oct-2023
2023 AGM Notice of Meeting and Proxy
17-Oct-2023
2023 AGM Letter to Shareholders and Proxy
13-Oct-2023
Quarterly Activities Report and Appendix 4C
28-Aug-2023
Nyrada Full Year Results FY2023
28-Aug-2023
Annual Report for year ended 30 June 2023
28-Aug-2023
Preliminary Final Report
28-Aug-2023
Appendix 4G and Corporate Governance Statement
28-Jul-2023
Quarterly Activities Report and Appendix 4C
20-Jul-2023
Nyrada Review of Operating Costs
26-Jun-2023
Cholesterol-Lowering Program Update
9-Jun-2023
Brain Injury Program Preclinical Development Update
26-May-2023
Cholesterol-Lowering Program Preclinical Studies Completed
26-Apr-2023
Quarterly Activities Report and Appendix 4C
11-Apr-2023
Cholesterol-Lowering Program Preclinical Development Update
24-Feb-2023
Nyrada Half Year Results FY2023
24-Feb-2023
Appendix 4D and Half Year Report to 31 December 2022
30-Jan-2023
Quarterly Activities Report and Appendix 4C
18-Jan-2023
Collaboration with Walter Reed and UNSW Extended to 2025
16-Jan-2023
Notification of cessation of securities - NYR
11-Jan-2023
Brain Injury Program Update
21-Nov-2022
Results of Meeting
21-Nov-2022
AGM Presentation by James Bonnar CEO
21-Nov-2022
Nyrada AGM 2022 Chairmans Address
18-Nov-2022
Nyrada Receives A$1.2M R&D Tax Incentive Rebate
27-Oct-2022
CEO Remuneration Update
26-Oct-2022
Quarterly Activities Report and Appendix 4C
18-Oct-2022
2022 AGM Letter to Shareholders and Proxy
18-Oct-2022
2022 AGM Notice of Meeting and Proxy
10-Oct-2022
Efficacy Study Published in Journal of Lipid Research
29-Sep-2022
Presentation to ShareCafe Hidden Gems Webinar
5-Sep-2022
Presentation to E&P Small Caps Health Care Conference
29-Aug-2022
Nyrada Reports Full Year FY2022 Results
29-Aug-2022
Annual Report to June 30 2022
29-Aug-2022
Preliminary Final Report
29-Aug-2022
Appendix 4G and Corporate Governance Statement
2-Aug-2022
Nyrada Board Changes
2-Aug-2022
Initial Director's Interest Notice - GM
2-Aug-2022
Final Director's Interest Notice - PM
26-Jul-2022
Quarterly Activities Report and Appendix 4C
20-Jul-2022
Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
29-Jun-2022
Cholesterol-Lowering Program Update
7-Jun-2022
Corporate Presentation
6-Jun-2022
Brain Injury Program Target Unveiled and Phase I Update
17-May-2022
European Patent to be Granted for Cholesterol-Lowering Drug
19-Apr-2022
Nyrada Quarterly Activities Report & Appendix 4C
30-Mar-2022
Investor Roadshow Presentation
29-Mar-2022
New Drug Offers Potential Oral Treatment for Concussion
2-Mar-2022
Presentation to Meet the CEO Life Sciences Edition
25-Feb-2022
Nyrada Half Year Results FY2022
25-Feb-2022
Appendix 4D and Half Year Report to 31 December 2021
21-Jan-2022
Nyrada Quarterly Activities Report & Appendix 4C
17-Jan-2022
Application for quotation of securities - NYR
17-Jan-2022
Change of Director's Interest Notice - ID
17-Jan-2022
Change of Director's Interest Notice - MF
17-Jan-2022
Change of Director's Interest Notice - RW
17-Jan-2022
Change of Director's Interest Notice - JM
17-Jan-2022
Change of Director's Interest Notice - CC
17-Jan-2022
Change of Director's Interest Notice - PM
12-Jan-2022
Nyrada Receives A$1.3M R&D Tax Incentive Rebate
4-Jan-2022
Brain Injury Program Update and Pathway to Phase I
22-Dec-2021
Cholesterol-Lowering Program Pathway to Phase I
10-Dec-2021
Release of Securities from Escrow
19-Nov-2021
Nyrada Annual General Meeting Results
19-Nov-2021
Annual General Meeting Presentation
19-Nov-2021
Nyrada AGM 2021 Chairman's Address
26-Oct-2021
Nyrada Quarterly Activities Report & Appendix 4C
19-Oct-2021
2021 AGM Notice of Meeting and Proxy
19-Oct-2021
2021 AGM Letter to Shareholders and Proxy
13-Sep-2021
Presentation to ASX Small and Mid-Cap Conference
3-Sep-2021
Updated Share Trading Policy
30-Aug-2021
Nyrada Reports Full Year FY2021 Results
30-Aug-2021
Annual Report to 30 June 2021
30-Aug-2021
Preliminary Final Report
30-Aug-2021
Appendix 4G and Corporate Governance Statement
13-Aug-2021
NYX-PCSK9i In Vivo Study Exploratory Analysis Results
30-Jul-2021
Nyrada Announces US Patent Grant for PCSK9 Inhibitor
27-Jul-2021
Nyrada Quarterly Activities Report & Appendix 4C
30-Jun-2021
Change of Director's Interest Notice - CC
30-Jun-2021
Change of Director's Interest Notice - ID
30-Jun-2021
Change of Director's Interest Notice - RW
30-Jun-2021
Change of Director's Interest Notice - MF
30-Jun-2021
Change of Director's Interest Notice - PM
30-Jun-2021
Change of Director's Interest Notice - JM
30-Jun-2021
Change in substantial holding
30-Jun-2021
Change in substantial holding
29-Jun-2021
Cleansing Statement
29-Jun-2021
Confirmation of Capital Structure, CDIs on Issue
29-Jun-2021
Notification regarding unquoted securities - NYR
29-Jun-2021
Application for quotation of securities - NYR
29-Jun-2021
Application for quotation of securities - NYR
29-Jun-2021
NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction
16-Jun-2021
Results of Meeting
15-Jun-2021
Improved Drug Candidate Selected for WRAIR Studies
11-May-2021
Notice of Extraordinary General Meeting/Proxy Form
6-May-2021
Nyrada Receives A$1.0M R&D Tax Incentive Rebate
5-May-2021
NYR Announces New Potent Cholesterol-Lowering Candidates
26-Apr-2021
Change of Registered Office and Principal Place of Business
20-Apr-2021
Nyrada Quarterly Activities Report & Appendix 4C
30-Mar-2021
Change in substantial holding
30-Mar-2021
Ceasing to be a substantial holder
30-Mar-2021
Change in substantial holding
30-Mar-2021
Cleansing Statement
30-Mar-2021
Appendix 2A
25-Mar-2021
Change in substantial holding
22-Mar-2021
Proposed issue of Securities - NYR
22-Mar-2021
Nyrada Receives Firm Commitments to Raise A$11 Million
18-Mar-2021
Nyrada Investor Presentation
17-Mar-2021
Trading Halt
5-Mar-2021
Change of Director's Interest Notice - JM
2-Mar-2021
Nyrada Newsletter February 2021
24-Feb-2021
Appendix 3G
24-Feb-2021
Change of Director's Interest Notice - MF
23-Feb-2021
Investor Presentation to Finance News Network CEO Showcase
22-Feb-2021
Nyrada Reports Half Year FY2021 Results
22-Feb-2021
Appendix 4D and Half Year Accounts
16-Feb-2021
Lapsing of balance of Unlisted SAB Options
16-Feb-2021
Cleansing Statement
16-Feb-2021
Appendix 2A
1-Feb-2021
NYR Secures Collaboration with Walter Reed and UNSW
29-Jan-2021
Trading Halt
28-Jan-2021
Nyrada Quarterly Activities Report & Appendix 4C
25-Jan-2021
Nyrada Reports Further Results from Cholesterol Study
22-Jan-2021
Unlisted Scientific Advisory Board Options Expiry 15 Feb 21
18-Jan-2021
Change of Director's Interest Notice - ID
18-Jan-2021
Appendix 3G
18-Jan-2021
Appendix 3G
18-Jan-2021
Appendix 3G
7-Jan-2021
Release of Securities from Escrow
6-Jan-2021
Change in substantial holding
21-Dec-2020
57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study
14-Dec-2020
Appointment of New Auditor
8-Dec-2020
Change in substantial holding
2-Dec-2020
Cleansing Statement
2-Dec-2020
Appendix 2A
26-Nov-2020
Change of Director's Interest Notice - JM
25-Nov-2020
Change of Director's Interest Notice - MF
25-Nov-2020
Appendix 2A
19-Nov-2020
Nyrada Annual General Meeting Results
19-Nov-2020
Presentation to 2020 Annual General Meeting of Shareholders
19-Nov-2020
Nyrada AGM 2020 Chairmans Address
16-Nov-2020
Release of Securities from Escrow
9-Nov-2020
Unlisted Convertible Note Options Expiring 30 November 2020
3-Nov-2020
2020 Annual General Meeting Reminder
19-Oct-2020
Letter to Shareholders and Proxy Form in relation to AGM
19-Oct-2020
Notice of Annual General Meeting and Proxy Form
13-Oct-2020
Nyrada Quarterly Activities Report & Appendix 4C
24-Sep-2020
Nyrada Newsletter September 2020
17-Sep-2020
Notification of Date of 2020 Annual General Meeting
11-Sep-2020
Change of Director's Interest Notice - JM
11-Sep-2020
Corporate Presentation for ShareCafe Hidden Gems Webinar
9-Sep-2020
Nyrada Investor Webinar
8-Sep-2020
Initial Director's Interest Notice - ID
8-Sep-2020
Final Director's Interest Notice - GK
8-Sep-2020
Annual Report to 30 June 2020
8-Sep-2020
Appendix 4G and Corporate Governance Statement
31-Aug-2020
FY 2020 Appendix 4E Preliminary Financial Report
31-Aug-2020
Nyrada Board Changes
30-Jul-2020
Nyrada Global Webcast Invitation
29-Jul-2020
Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure
23-Jul-2020
Nyrada Roadshow Corporate Presentation
22-Jul-2020
Appendix 4C - June 2020 Quarterly Report
15-Jul-2020
Nyrada Brain Injury Drug Pharmacokinetic Study Results
9-Jul-2020
Nyrada Brain Injury Data Published by Premier US Military Health Conference
8-Jul-2020
Change in substantial holding
6-Jul-2020
Nyrada Cholesterol-Lowering Drug Study Results
25-Jun-2020
Nyrada Newsletter June 2020
24-Jun-2020
Corporate Presentation for the Reach Markets Virtual Event
25-May-2020
Milestone Achieved in the Nyrada Brain Injury Program
30-Apr-2020
Nyrada Preclinical Program & Corporate Update Presentation
27-Apr-2020
Change of Director's Interest Notice - JM
22-Apr-2020
Appointment of New Chief Financial Officer
20-Apr-2020
Preclinical Program & Corporate Update Global Webinar
14-Apr-2020
Appendix 4C - March 2020 quarterly
6-Apr-2020
Nyrada Newsletter Released
16-Mar-2020
Update on Progress in Nyrada Programs
27-Feb-2020
Nyrada Inc. Corporate Presentation February 2020
25-Feb-2020
Appendix 4D and Half Year Accounts
11-Feb-2020
Significant advance in Nyrada PCSK9i program published
20-Jan-2020
Nyrada Inc - Chairman's letter to shareholders
20-Jan-2020
Becoming a substantial holder
17-Jan-2020
Nyrada Inc - Corporate Presentation
16-Jan-2020
NOX: Listing of Nyrada Inc. spin-off on ASX
16-Jan-2020
NYR Commences Trading on the ASX
16-Jan-2020
Becoming a substantial holder
16-Jan-2020
Becoming a substantial holder
16-Jan-2020
Initial Director's Interest Notice
16-Jan-2020
Initial Director's Interest Notice
16-Jan-2020
Initial Director's Interest Notice
16-Jan-2020
Initial Director's Interest Notice
16-Jan-2020
Initial Director's Interest Notice
16-Jan-2020
Initial Director's Interest Notice
15-Jan-2020
Regulation S-Foreign Ownership Restrictions
14-Jan-2020
Confirmation and Waiver under ASX Listing Rules
14-Jan-2020
Pre-Quotation Disclosure
14-Jan-2020
Updated Pro-forma - Financial Position and Commitments
14-Jan-2020
Securities Trading Policy
14-Jan-2020
Capital Structure and Restricted Securities
14-Jan-2020
Financial Statements Year End 30 June 2019
14-Jan-2020
Financial Statements Year End 30 June 2018
14-Jan-2020
Corporate Governance Statement
14-Jan-2020
Equity Incentive Plan
14-Jan-2020
Amended and Restated Certificate of Incorporation and Bylaws
14-Jan-2020
Supplementary Prospectus
14-Jan-2020
Prospectus
14-Jan-2020
Appendix 1A, Information Form and Checklist, Annexure 3
14-Jan-2020
Distribution Schedule
14-Jan-2020
Top 20 Securityholders
14-Jan-2020
ASX Market Release - Admission and Quotation